Lyell Immunopharma SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 4, 2026, 4:14 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedLyell Immunopharma Q3 2026 net loss widens to $45.5 million as R&D rises; revenue in line at $3 thousand; $80.0 million private placement announced
8-KNov. 4, 2026, 9:05 a.m. ETView on SEC.gov
Unregistered sales of equity securities
AI summary, unreviewedLyell Immunopharma Announces $80.0 Million Private Placement of 7,428,040 Shares at $10.77 Per Share
8-KSept. 10, 2026, 4:13 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
8-KAug. 6, 2026, 4:14 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits